PF 06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta®): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
figureposted on 2020-07-06, 16:46 authored by Shahrzad Moosavi, Troy Borema, Reginald Ewesuedo, Stuart Harris, Jeffrey Levy, Thomas B. May, Martin Summers, Jeffrey S. Thomas, Jeffrey Zhang, Hsuan-Ming Yao
The above summary slide and plain language summary represents the opinions of the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.